Skip to main content
SpringerLink
Log in

Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

The vitamin K antagonists (VKAs) have been the standard (and only) oral anticoagulants used for the long-term treatment or prevention of venous thromboembolism or stroke in patients with atrial fibrillation. The coagulopathy induced by VKAs can be reversed with vitamin K, and in urgent situations, the vitamin K-dependent coagulation factors can be replaced by transfusion. In the last decade, a new class of oral anticoagulants has been developed, direct oral anticoagulants that bind to a specific coagulation factor and neutralize it. These compounds were shown to be effective and safe compared with the VKAs and were licensed for specific indications, but without a specific reversal agent. The absence of a reversal agent is a barrier to more widespread use of these agents. Currently, for the management of major life-threatening bleeding with the direct oral anticoagulants, most authorities recommend the use of four factor prothrombin complex concentrates. There are now three reversal agents in development and poised to enter the market. Idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the USA. Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. Ciraparantag is an antidote targeted to reverse the direct thrombin and factor Xa inhibitors as well as the indirect inhibitor enoxaparin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ, for the American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(No. 2 Suppl):e1S–e801S.

  2. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Eng J Med. 2011;365:2002–12.

    Article  CAS  Google Scholar 

  3. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147:755–65.

    Article  PubMed  Google Scholar 

  4. Shepherd G, Mohorn P, Yacoub K, May DW. Adverse drug reaction deaths reported in United States Vital Statistics, 1999–2006. Ann Pharmacother. 2012;46:169–75.

    Article  PubMed  Google Scholar 

  5. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. The pharmacology and management of the vitamin K antagonists: ACCP evidence-based clinical practice guidelines. Chest. 2008;133:160S–98S.

    Article  CAS  PubMed  Google Scholar 

  6. Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2_suppl):e120S–151S.

  7. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124:2450–8.

    Article  CAS  PubMed  Google Scholar 

  8. Skaistis J, Tagami T. Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin K antagonists: a systematic review and meta-analysis. PLoS One. 2015;. doi:10.1371/journal.pone.0137444.

    PubMed  PubMed Central  Google Scholar 

  9. Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128:2325–32.

    Article  CAS  PubMed  Google Scholar 

  10. Piccini JP, Garg J, Patel MR, Lokhnygina Y, Goodman SG, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Mahaffey KW, Singer DE, Califf RM, Fox KAA. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2014;35:1873–80.

    Article  CAS  PubMed  Google Scholar 

  11. Costin J, Ansell J, Laulicht B, Bakhru S, Steiner S. Reversal agents in development for the new oral anticoagulants. Postgrad Med. 2014;126:19–24.

    Article  PubMed  Google Scholar 

  12. Stanworth SJ, Hyde CJ, Murphy MF. Evidence for indications of fresh frozen plasma. Transfus Clin Biol. 2007;14:551–6.

    Article  CAS  PubMed  Google Scholar 

  13. Sokolovic M, Pastores SM. Transfusion therapy and acute lung injury. Expert Rev Respir Med. 2010;4:387–93.

    Article  PubMed  Google Scholar 

  14. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S–84S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Khorsand N, Kooistra HAM, van Hest RM, Veeger NJGM, Meijer K. A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy. Thromb Res. 2014;135:9–19.

    Article  PubMed  Google Scholar 

  16. Sarode R, Milling TJ, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN. Efficacy and Safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circ. 2013;128:1234–43.

    CAS  Google Scholar 

  17. Grottke O, Braunschweig T, Spronk HMH, Esch S, Rieg AD, van Oerle R, ten Cate H, Fitzner C, Tolba R, Rossaint R. Increasing concentrations of prothrombin complex concentrate induce DIC in a pig model of coagulopathy with blunt liver injury. Blood. 2011;118:1943–51.

    Article  CAS  PubMed  Google Scholar 

  18. Dusel CH, Grundmann C, Eich S, Seitz R, König H. Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis. 2004;15:405–11.

    Article  CAS  PubMed  Google Scholar 

  19. Dentali F, Marches C, Pierfranceschi MG, Crowther M, Garcia D, Hylek E, Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. Thromb Haemost. 2011;106:429–38.

    Article  CAS  PubMed  Google Scholar 

  20. Quinlan DJ, Eikelboom JW, Weitz JI. Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. Circ. 2013;128:1179–81.

    Google Scholar 

  21. Roldan V, Marin F. Pro: antidote for new anticoagulants—specific target of inhibition requires a specific target for neutralisation. Thromb Haemost. 2012;108:621–2.

    Article  CAS  PubMed  Google Scholar 

  22. Eerenberg ES, Levi M, Buller HR. Contra: antidotes for novel anticoagulants—do we really need them. Thromb Haemost. 2012;108:623–4.

    Article  CAS  PubMed  Google Scholar 

  23. Miller MP, Trujillo TC, Nordenholz KE. Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants. Am J Emerg Med. 2014;32:375–82.

    Article  PubMed  Google Scholar 

  24. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. A randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573–9.

    Article  CAS  PubMed  Google Scholar 

  25. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. Thromb Haemost. 2012;108:217–24.

    Article  CAS  PubMed  Google Scholar 

  26. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost. 2012;107:253–9.

    Article  CAS  PubMed  Google Scholar 

  27. Honickel M, Braunschweig T, van Ryn J, ten Cate H, Spronk HMH, Rossaint R, Grottke O. Prothrombin complex concentrate is effective in treating the anticoagulant effects of dabigatran in a porcine polytrauma model. Anesthesiology. 2015;123:1350–61.

    Article  CAS  PubMed  Google Scholar 

  28. Honickel M, Maron B, van Ryn L, Braunschweig T, ten Cate H, Spronk HMH, Rossaint R, Grottke O. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. Thromb Haemost. 2015. doi:10.1160/TH15-03-0266 (publish online Sep 3).

  29. van Ryn J, Schure J, Kink-Eiband M, Clemens A. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology. 2014;120:1429–40.

    Article  PubMed  Google Scholar 

  30. Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost. 2014;111:189–98.

    Article  CAS  PubMed  Google Scholar 

  31. Perzhorn E, Gruber A, Tinel H, Marzec LM, Buetehorn U, Buchmueller A, Heitmeier S, Laux V. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost. 2013;110:162–72.

    Article  Google Scholar 

  32. Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield WP. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost. 2012;10:1830–40.

    Article  CAS  PubMed  Google Scholar 

  33. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost. 2012;10:1841–8.

    Article  CAS  PubMed  Google Scholar 

  34. Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman JM, Leyte A. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban. J Thromb Haemost. 2013;11:1111–8.

    Article  CAS  PubMed  Google Scholar 

  35. Zahir H, Brown KS, Vandell A, Desai M, Maa JF, Dishy V, Lomeli B, Feussner A, Feng W, He L, Grosso MA, Lanz HJ, Antman EM. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2014;131:82–90.

    Article  PubMed  Google Scholar 

  36. Jackson LR, Becker RC. Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. J Thromb Thrombolysis. 2014;37:380–91.

    Article  CAS  PubMed  Google Scholar 

  37. Siegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis. 2015;39:395–402.

    Article  CAS  PubMed  Google Scholar 

  38. Kaatz S, Kouides PA, Garcia DA, Spyropoulos AC, Crowther M, Douketis JD, Chan AKC, James A, Moll S, Ortel TL, van Cott EM, Ansell J. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87:S141–5.

    Article  CAS  PubMed  Google Scholar 

  39. Miesbach W, Seifried E. New direct oral anticoagulants-current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost. 2012;108:625–32.

    Article  CAS  PubMed  Google Scholar 

  40. Schiele F, van Ryn J, Canada K, Newsome C, Sepuveda E, Park J, Nar J, Litzenburger T. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–62.

    Article  CAS  PubMed  Google Scholar 

  41. Glund S, Stangier J, Schmohl M, De Smet M, Gansser D, Lang B, Moschetti V, Ramael S, Reilly PA. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Circulation. 2013;128:A17765.

    Google Scholar 

  42. Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kapmhusien PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20.

    Article  CAS  PubMed  Google Scholar 

  43. Grottke O, Honickel M, van Ryn J, ten Cate H, Rossaint R, Sprink HM. Idarucizumab, a specific dabigatran reversal agent, reduces blood loss in a porcine model of trauma with dabigatran anticoagulation. J Am Coll Cardiol. 2015;66:1518–9.

    Article  PubMed  Google Scholar 

  44. Praxbind package insert. http://us.boehringer-ingelheim.com/content/dam/internet/opu/us_EN/documents/Media_Press_Releases/2015/Praxbind.pdf. Accessed 20 Nov 2015.

  45. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446–51.

    Article  CAS  PubMed  Google Scholar 

  46. Shah N, Rattu MA. Reversal agents for anticoagulants: focus on andexanet alfa. Am Student Res J. 2014;1:16–28.

    Google Scholar 

  47. Crowther M, Vandana M, Michael K, Genmin L, Conley PB, Hollenbach S, Castillo J, Hutchaleelaha A, Karbarz M, Lin JP, Barron L, Russell S, Levy GG, Connolly S, Curnutte JT. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa, an antidote for FXa inhibitors. Blood. 2013;122:3636 (abstract).

    Google Scholar 

  48. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:511–520. doi:10.1056/NEJMoa1510991.

    Article  Google Scholar 

  49. Gold AM, Crowther M, Levy G, Lu G, Leeds J, Barron L, Conley P, Castillo J, Curnutte J, Connolly S. ANNEXA™-R: a phase 3 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in older subjects by andexanet alfa, a universal antidote for factor Xa inhibitors. JACC. 2015;65:A23 (abstract).

    Article  Google Scholar 

  50. Crowther M, Gold A, Lu G, Leeds JM, Wiens BL, Mathur V, Castillo J, Conley PB, Connolly S, Curnutte JT. ANNEXA-A Part 2: a phase 3 randomized, double-blind, placebo-controlled trial demonstrating sustained reversal of apixaban-induced anticoagulation in older subjects by andexanet alfa, a universal antidote for factor Xa inhibitors. J Thromb Haemost. 2015;13(Suppl 2):84 (LB004 abstract).

    Google Scholar 

  51. Crowther M, Lu G, Conley P, Leeds J, Castillo J, Levy G, Connolly S, Curnutte J. Reversal of factor Xa inhibitors-induced anticoagulation in healthy subjects by andexanet alfa. Crit Care Med 2014;42:pA1469.

  52. Laulicht B, Bakhru S, Jiang X, et al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. Presented at the 24th Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, June 29–July 4. 2013. Abstract (http://www.eventure-online.com/eventure/publicAbstractView.do?id=226718&congressId=6839). Accessed 27 Jan 2016.

  53. Bakhru S, Laulicht B, Jiang X, Chen I, Pan D, Grosso M, Morishima Y, Brown K, Masumoto H, Costin J, Steiner S. PER977: a synthetic small molecule which reverses over-dosage and bleeding by the new oral anticoagulants. Circ. 2013;128:A18809 (abstract).

    Google Scholar 

  54. Bakhru S, Laulicht B, Jiang X, Chen L, Grosso M, Morishima Y, Brown K, Mercuri M, Masumoto H, Costin J, Steiner S. Reversal of anticoagulant-induced bleeding in external and internal bleeding models by PER977, a small molecule anticoagulant antidote. Circ. 2014;130:A19361 (abstract).

    Google Scholar 

  55. Ansell JE, Bakhru S, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Eng J Med. 2014;2014(339):2141–2.

    Article  Google Scholar 

  56. Laulicht B, Bakhru S, Steiner S, Brown K, Grosso M, Lanz H, Mercuri M, Costin J. PER977 (ciraparantag) reverses edoxaban anticoagulation at steady state and has no effect on re-anticoagulation at the next scheduled dose [Abstract No. 4971]. Eur Heart J 2015;36(Abstract Supplement):859–60.

  57. Costin J, Laulicht B, Bakhru S, Laulicht B, Steiner S. PER977 reverses low molecular weight heparin in addition to IIa and Xa new oral anticoagulants. J Am Coll Cardiol. 2015:65(10_S)(abstract). doi:10.1016/S0735-1097/(15)62056-3.

  58. Costin J, Ansell J, Bakhru S, Laulicht B, Solomon S. The new oral anticoagulants: clinical use and reversal agent development. ISBT Science Series. 2015;10(Suppl 1):324–31.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hofstra North Shore/LIJ School of Medicine, Hempstead, NY, USA

    Jack E. Ansell

  2. 15 Waterview Way, Long Branch, NJ, 07740, USA

    Jack E. Ansell

Authors
  1. Jack E. Ansell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jack E. Ansell.

Ethics declarations

Disclosures

Dr. Ansell reports consultant activities and honoraria from Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Janssen, and Daiichi Sankyo. Dr. Ansell is a member of the Scientific Advisory Board for Perosphere and has equity interest in Perosphere.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ansell, J.E. Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options. Am J Cardiovasc Drugs 16, 163–170 (2016). https://doi.org/10.1007/s40256-016-0162-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-016-0162-7

Keywords

Search

Navigation